Ποια είναι η τιμή για Gentian Diagnostics AS (GENT)

Η τιμή για Gentian Diagnostics AS (GENT) είναι $4.07

Ποια είναι η κεφαλαιοποίηση αγοράς για Gentian Diagnostics AS (GENT)

Η κεφαλαιοποίηση αγοράς για Gentian Diagnostics AS (GENT) είναι $62.87M

Gentian Diagnostics AS (GENT) Τιμή και Κεφαλαιοποίηση Αγοράς

Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. The company also develops faecal calprotectin immunoassay turbo that offers results of calprotectin concentration in stool supporting diagnosis of inflammatory bowel disease; and faecal pancreatic elastase immunoassay turbo, which allows analysis of pancreatic elastase in stool to aid in diagnosis of pancreatic exocrine insufficiency. Gentian Diagnostics ASA was founded in 2001 and is headquartered in Moss, Norway.

Η τιμή για GENT	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$337,119 $62.87M	NVDA	$5.211T	+8,289,352.54%
$294,125 $62.87M	AAPL	$4.547T	+7,232,171.57%
$269,267 $62.87M	GOOG	$4.162T	+6,620,933.30%
$232,414 $62.87M	MSFT	$3.593T	+5,714,764.72%
$180,667 $62.87M	AMZN	$2.793T	+4,442,347.62%

Η τιμή για GENT

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$337,119 $62.87M